-
Loading metrics
First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis
- Lutz Renders,
- Klemens Budde,
- Christian Rosenberger,
- Rachel van Swelm,
- Dorine Swinkels,
- Frank Dellanna,
- Werner Feuerer,
- Ming Wen,
- Christiane Erley,
- Birgit Bader
x
- Published: March 27, 2019
- https://doi.org/10.1371/journal.pone.0212023